Literature DB >> 7917770

Concurrent use of more than one major psychotropic drug (polypsychopharmacy) in out-patients--a prescription database study.

J U Rosholm1, J Hallas, L F Gram.   

Abstract

1. In order to assess the prevalence of concurrent use of more than one major psychotropic drug (polypsychopharmacy) in out-patients, a prescription database study was conducted in the Odense area for a period of 2 years. 2. During the index period 5.12% of the inhabitants purchased major psychotropic drugs. Of these, 14% had a period of polypsychopharmacy recorded. The age-specific prevalence of users increased with age, the prevalence for over 90 years of age was 18%. Sixty-seven per cent of the psychotropic drug users were women. 3. For neuroleptic and antidepressant users, about 20% were subject to polypsychopharmacy, for lithium 61%. The most prevalent combination was neuroleptics-neuroleptics. In none of the 10 most prevalent combinations were the mean daily doses significantly lower on polypsychopharmacy compared with single drug regimens, in two they were higher. 4. Polypsychopharmacy with psychotropic drugs was frequent in out-patients. In polypsychopharmacy daily doses were not lowered in order to limit side effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7917770      PMCID: PMC1364811          DOI: 10.1111/j.1365-2125.1994.tb04300.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  Polypsychopharmacy.

Authors:  S Sturges; M Brown
Journal:  Bull Menninger Clin       Date:  1975-05

2.  Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports.

Authors:  W Steiner; R Fontaine
Journal:  Biol Psychiatry       Date:  1986-09       Impact factor: 13.382

3.  Interaction of fluoxetine with tricyclic antidepressants.

Authors:  D A Vaughan
Journal:  Am J Psychiatry       Date:  1988-11       Impact factor: 18.112

4.  Psychotropic drug use and polypharmacy in a general hospital.

Authors:  C Salzman
Journal:  Gen Hosp Psychiatry       Date:  1981-03       Impact factor: 3.238

5.  Polypsychopharmacy revisited.

Authors:  M S Rapp; A Kaplan
Journal:  Can J Psychiatry       Date:  1981-12       Impact factor: 4.356

6.  Automated review system for orders of psychotropic drugs.

Authors:  E Laska; C Siegel; G Simpson
Journal:  Arch Gen Psychiatry       Date:  1980-07

7.  [Prescription of psychopharmaceuticals in general practice. 1. A registry study in the county of Arhus].

Authors:  M Holm; F Olesen
Journal:  Ugeskr Laeger       Date:  1989-08-21

8.  Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.

Authors:  L F Gram; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

9.  Why are psychotropic drugs prescribed to out-patients? A methodological study.

Authors:  U Bergman; M Dahlström; C Gunnarsson; B Westerholm
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

10.  Drug treatment of psychiatric patients in general practice.

Authors:  P Tyrer
Journal:  Br Med J       Date:  1978-10-07
View more
  6 in total

Review 1.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

2.  Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.

Authors:  R A Kiivet; A Llerena; M L Dahl; L Rootslane; J Sánchez Vega; T Eklundh; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

3.  Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.

Authors:  J G Shin; K Kane; D A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

Review 4.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Pharmacotherapy of insomnia: practice and prospects.

Authors:  J Dingemanse
Journal:  Pharm World Sci       Date:  1995-05-26

Review 6.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.